Medicamen Biotech's Q1 FY 2026-27 Quarterly Results

Result Summary

• Medicamen Biotech Ltd reported a 21.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 12.0%.
• Its expenses for the quarter were down by 19.4% QoQ and up 11.6% YoY.
• The net profit decreased 58.4% QoQ and increased 15.6% YoY.
• The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.36 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Medicamen Biotech Ltd is a pharmaceutical company that operates within the biotechnology industry. The company is primarily engaged in the development, manufacturing, and marketing of pharmaceutical formulations. Medicamen Biotech Ltd specializes in the production of a wide range of pharmaceutical products, including tablets, capsules, syrups, and ointments. The company is known for its focus on research and development, aiming to provide high-quality and affordable healthcare solutions. As of the latest information available, there have been no major recent developments disclosed in the provided data. For more specific and recent developments, additional data or current company reports would be required.

Revenue

In Q1FY27, Medicamen Biotech Ltd reported a total income of ₹48.76 crores, which represents a decline of 21.8% from the previous quarter (Q4FY26) where it was ₹62.38 crores. However, on a year-over-year basis, there was an increase of 12.0% compared to Q1FY26, when the total income was ₹43.52 crores. This data indicates fluctuations in the company's revenue over the quarters, with a significant decrease from the last quarter but an overall increase from the same period in the previous year. The quarterly decline could be attributed to various market factors or operational adjustments that are not specified in the provided financial data.

Profitability

The profitability of Medicamen Biotech Ltd saw a noticeable change in Q1FY27. The profit before tax (PBT) stood at ₹2.57 crores, which is a reduction of 49.2% from Q4FY26, where it was ₹5.06 crores. However, there was a 20.7% increase from Q1FY26, where the PBT was ₹2.13 crores. Tax expenses for Q1FY27 were ₹0.73 crores, showing an increase of 19.7% from the previous quarter and 37.7% from the previous year. Consequently, the profit after tax (PAT) for Q1FY27 was ₹1.85 crores, declining by 58.4% from Q4FY26 but increasing by 15.6% from Q1FY26. Earnings per share (EPS) followed a similar trend, reaching ₹1.36, down by 58.5% quarter-over-quarter but up by 15.3% year-over-year.

Operating Metrics

During Q1FY27, the total expenses for Medicamen Biotech Ltd were ₹46.19 crores, reflecting a decrease of 19.4% from Q4FY26, where expenses were ₹57.32 crores. Compared to Q1FY26, where total expenses were ₹41.38 crores, there was an increase of 11.6%. This fluctuation in expenses is mirrored in the total income trends, suggesting operational adjustments within the company. The changes in income and expenses have impacted the company’s profitability metrics. The decline in both total income and expenses from the previous quarter indicates a potential shift in the company's operational strategy or market conditions, while year-over-year increases suggest potential growth or expansion activities compared to the previous year.